Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Among authors: oyanagi j. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Izumi M, Ogawa K, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Koh Y, Kawaguchi T. Matsumoto Y, et al. Among authors: oyanagi j. Cancer Sci. 2019 Oct;110(10):3244-3254. doi: 10.1111/cas.14156. Epub 2019 Aug 30. Cancer Sci. 2019. PMID: 31368625 Free PMC article.
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N. Akamatsu H, et al. Among authors: oyanagi j. Oncologist. 2020 Apr;25(4):e679-e683. doi: 10.1634/theoncologist.2019-0299. Epub 2019 Nov 19. Oncologist. 2020. PMID: 32297443 Free PMC article.
Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
Oyanagi J, Koh Y, Sato K, Teraoka S, Tokudome N, Hayata A, Akamatsu H, Ozawa Y, Nakanishi M, Ueda H, Yamamoto N. Oyanagi J, et al. Clin Lung Cancer. 2021 Nov;22(6):e833-e841. doi: 10.1016/j.cllc.2021.04.007. Epub 2021 Apr 27. Clin Lung Cancer. 2021. PMID: 34049821 Free article.
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.
Harutani Y, Ozawa Y, Murakami E, Sato K, Oyanagi J, Akamatsu H, Yoshikawa T, Shibaki R, Sugimoto T, Furuta K, Teraoka S, Tokudome N, Hayata A, Ueda H, Nakanishi M, Koh Y, Yamamoto N. Harutani Y, et al. Among authors: oyanagi j. Cancer Immunol Immunother. 2022 Sep;71(9):2109-2116. doi: 10.1007/s00262-022-03141-4. Epub 2022 Jan 16. Cancer Immunol Immunother. 2022. PMID: 35037070 Free PMC article.
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Yoshimoto N, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Hirata K, Koh Y, Kawaguchi T. Matsumoto Y, et al. Among authors: oyanagi j. Lung Cancer. 2020 Jan;139:80-88. doi: 10.1016/j.lungcan.2019.10.029. Epub 2019 Nov 2. Lung Cancer. 2020. PMID: 31751804
[No title available]
[No authors listed] [No authors listed] PMID: 35617519
25 results